Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
110 stopped studies mapped to Chronic Myeloid Leukemia, BCR-ABL1 Positive and descendants · 75% state a reason
Over the 110 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT02174445 | An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of…(DECLINE) | Phase 3 | terminated | Jun 25, 2014 | Prof. Dr. Nikolas von Bubnoff | very slow recruitment rate and a lot of pat. didn't fulfil BCR-ABL requirements | Enrollment / accrual |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | Phase 2 | terminated | Dec 11, 2015 | St. Petersburg State Pavlov Medical University | Poor recruitment | Enrollment / accrual |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT02730195 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic… | Phase 2 | terminated | Apr 6, 2016 | Emory University | not stated | Not stated |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02709083 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic… | Phase 2 | terminated | Mar 15, 2016 | Emory University | Original principal investigator left institution | Investigator |
| NCT01866553 | Nilotinib Plus Pegylated Interferon-α2b in CML | Phase 2 | terminated | May 31, 2013 | Amsterdam UMC, location VUmc | insufficient enrollment | Enrollment / accrual |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic… | Phase 1 | terminated | Apr 5, 2016 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT01490775 | Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib)… | N/A | terminated | Dec 13, 2011 | Rex Cancer Center, Raleigh, NC | Study was terminated due to lack of funding | Funding |
| NCT01490983 | Telemonitoring Study - for Chronic Myeloid Leukemia (CML) | N/A | terminated | Dec 13, 2011 | Rex Cancer Center, Raleigh, NC | Terminated due to lack of funding | Funding |
| NCT01761695 | Chronic Myelod Leukemia Registry at Asan Medical Center | — | terminated | Jan 7, 2013 | Asan Medical Center | The PI resigned the institute. The rest investigators at the institute decided to terminate the… | Other (stated, no rule matched) |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | Phase 1 / Phase 2 | terminated | Jan 15, 2010 | Everett Meyer | Safety | Safety / toxicity |
| NCT02204722 | A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients(IDEAL) | Phase 4 | terminated | Jul 30, 2014 | Dong-A ST Co., Ltd. | Sponsor's decision to halt the study. | Sponsor / business decision |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood… | Phase 2 | terminated | Aug 24, 2016 | Emory University | not stated | Not stated |
| NCT00593554 | Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies | Phase 2 | terminated | Jan 15, 2008 | Sherif S. Farag | Slow accrual | Enrollment / accrual |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | Phase 2 | terminated | Mar 27, 2012 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A… | N/A | terminated | Feb 26, 2010 | Fred Hutchinson Cancer Center | Funding withdrawal | Funding |
| NCT02259348 | Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following… | Phase 2 | terminated | Oct 8, 2014 | St. Jude Children's Research Hospital | Investigator's decision. | Investigator |
| NCT01605981 | Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated…(MACS1881) | Phase 4 | withdrawn | May 25, 2012 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell… | Phase 2 | terminated | Jul 25, 2014 | Celldex Therapeutics | not stated | Not stated |
| NCT02086487 | Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on…(NISRI) | Phase 4 | terminated | Mar 13, 2014 | King Abdullah International Medical Research Center | Because of many unseen obstacles resulted in poor accrual, study is terminated. | Enrollment / accrual |
| NCT01749111 | Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin…(CICLODECH) | Phase 3 | terminated | Dec 13, 2012 | Hospital Israelita Albert Einstein | Lack of accrual | Enrollment / accrual |
| NCT01621477 | T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell… | Phase 2 | terminated | Jun 18, 2012 | St. Jude Children's Research Hospital | Study was terminated in August 2016 due to replacement by a new study. | Other (stated, no rule matched) |
| NCT00052598 | Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or… | Phase 1 / Phase 2 | terminated | Jan 27, 2003 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01073436 | Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid… | — | terminated | Feb 23, 2010 | University of Michigan Rogel Cancer Center | Closed prematurely due to low accrual. | Enrollment / accrual |
| NCT02115672 | Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in… | Phase 1 / Phase 2 | withdrawn | Apr 16, 2014 | Sheba Medical Center | loss of support | Other (stated, no rule matched) |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With… | Phase 2 | withdrawn | Jul 27, 2012 | University of Medicine and Dentistry of New Jersey | Funding unavailable | Funding |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous… | — | terminated | Sep 16, 2005 | Stanford University | not stated | Not stated |
| NCT02663648 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders | — | withdrawn | Jan 26, 2016 | Shandong University | No eligible patient was enrolled. | Enrollment / accrual |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced… | Phase 2 / Phase 3 | withdrawn | Jul 7, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT01169753 | Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients | N/A | terminated | Jul 26, 2010 | M.D. Anderson Cancer Center | Slow Enrollment | Enrollment / accrual |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | Phase 1 | terminated | Mar 12, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT00464113 | Study of XL228 in Subjects With Chronic Myeloid Leukemia or… | Phase 1 | terminated | Apr 20, 2007 | Exelixis | Sponsor decision | Sponsor / business decision |
| NCT01188889 | RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease. | Phase 1 / Phase 2 | withdrawn | Aug 26, 2010 | University of Michigan Rogel Cancer Center | Unable to obtain sufficient funding. | Funding |
| NCT00114959 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic… | Phase 2 | terminated | Jun 21, 2005 | ChemGenex Pharmaceuticals | Poor enrollment | Enrollment / accrual |
| NCT01650805 | Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC) | Phase 3 | terminated | Jul 26, 2012 | Ariad Pharmaceuticals | Study terminated based on evaluation of safety data. | Safety / toxicity |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01426334 | Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia… | Phase 1 | terminated | Aug 31, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00672152 | A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following…(WT-1) | Phase 1 | terminated | May 6, 2008 | Michael Morse, MD | low accrual | Enrollment / accrual |
| NCT00301769 | SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic… | Phase 1 | terminated | Mar 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01159301 | Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid… | Phase 1 | terminated | Jul 9, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101231 | Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,… | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00023920 | Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic… | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00101088 | Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | Phase 1 | terminated | Jan 10, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00790855 | Bendamustine in Acute Leukemia and MDS | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | M.D. Anderson Cancer Center | Lack of Response | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 2, 2019source: clinicaltrials